11 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.
Sterling Winthrop Pharmaceuticals Research Division
Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones.
Sterling Winthrop Pharmaceuticals Research Division
Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles.
Sterling Winthrop Pharmaceuticals Research Division
Keto/enol epoxy steroids: a new structural class of HIV-1 Tat inhibitors.
Sterling Winthrop Pharmaceuticals Research Division
5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.
Sterling Winthrop Pharmaceuticals Research Division
Phosphonates and phosphinates: novel leaving groups for benzisothiazolone inhibitors of human leukocyte elastase.
Sterling Winthrop Pharmaceuticals Research Division
Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group.
Sterling Winthrop Pharmaceuticals Research Division
Structure determination, pharmacological evaluation, and structure-activity studies of a new cyclic peptide substance P antagonist containing the new amino acid 3-prenyl-beta-hydroxytyrosine, isolated from Aspergillus flavipes.
Sterling Winthrop Pharmaceuticals Research Division
A novel class of cyclic beta-dicarbonyl leaving groups and their use in the design of benzisothiazolone human leukocyte elastase inhibitors.
Sterling Winthrop Pharmaceuticals Research Division
Novel and potent adenosine 3',5'-cyclic phosphate phosphodiesterase III inhibitors: thiazolo[4,5-b][1,6]naphthyridin-2-ones.
Sterling Winthrop Pharmaceuticals Research Division